Clinicopathologic Characteristics of Papillary Microcarcinoma in the Elderly

Jin Kim Won; Jung Bae Min; Seon Yi Yang; Kyung Jeon Yun; Soo Kim Sang; Hyun Kim Bo; Joo Kim In

doi:10.11106/jkta.2013.6.1.69

Journal List > J Korean Thyroid Assoc > v.6(1) > 1056544

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Won, Min, Yang, Yun, Sang, Bo, and In: Clinicopathologic Characteristics of Papillary Microcarcinoma in the Elderly

Original Article

J Korean Thyroid Assoc 2013;6(1):69-74.

Published online: 3 May 2013

DOI: https://doi.org/10.11106/jkta.2013.6.1.69

Clinicopathologic Characteristics of Papillary Microcarcinoma in the Elderly

Jin Kim Won, Jung Bae Min, Seon Yi Yang, Kyung Jeon Yun, Soo Kim Sang, Hyun Kim Bo, Joo Kim In

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Busan, Korea

²Biomedical Research Institute, Pusan National University Hospital, Busan, Korea

Address reprint requests to In Joo Kim, MD, PhD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea Tel: 82-51-240-7224, Fax: 82-51-254-3127, E-mail: injkim@pusan.ac.kr

Received 11 April 2013 Accepted 7 May 2013

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and Objectives

Older patients show more aggressive features in papillary thyroid carcinoma (PTC). However, data about clinicopathologic features of older patients in papillary thyroid microcarcinoma (PTMC) are limited. Presently, we investigated the difference of clinicopathologic features in PTMC according to age.

Materials and Methods

A total of 820 PTMC patients (82 males, 10%; 738 females, 90%) who underwent total thyroidectomy at Pusan National University Hospital were enrolled. The patients were divided into three age groups: group 1 (44 years or younger, n=230), group 2 (45-64 years, n=513), and group 3 (65 years or older, n=77).

Results

Extrathyroidal extension was 33% in group 1, 32.2% in group 2, and 31.2% in group 3 (p=0.948). There was no significant difference of lymph node metastasis between the groups: N0 (59.1% vs. 67.8% vs. 70.1%), N1a (37.4% vs. 28.8% vs. 26%), and N1b (3.5% vs. 3.3% vs. 3.9%) (p=0.159). Of the 820 patients, 526 (64.1%) were diagnosed as early stage (stage I, II) PTMC and 294 (35.9%) were diagnosed as advanced stage (stage III, IV) PTMC. The proportion of patients with each stage was significantly different between the groups (p<0.001). However, there was no significantly difference in the stage over 45 years old. Of the 820 patients, 517 were evaluated BRAF^V600E mutation. There was no difference in prevalence between each group.

Conclusion

There was no statistically significant difference of clinicopathologic features between the groups, indicating that old age itself was not associated with unfavorable clinicopathologic features in PTMC.

Keywords: Papillary thyroid microcarcinoma, Age, Clinicopathologic features

References

1. Vasileiadis I, Karakostas E, Charitoudis G, Stavrianaki A, Kapetanakis S, Kouraklis G, et al. Papillary thyroid micro-carcinoma: clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest. 2012; 42(6):657–64.

2. Lee NS, Bae JS, Jeong SR, Jung CK, Lim DJ, Park WC, et al. Rsk fctors of lmph node metastasis in papillary thyroid microcarcinoma. J Korean Surg Soc. 2010; 78(2):82–6.

3. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer. TNM classification of malignant tumours. 7th ed.Chichester, West Sussex, England: Wiley-Blackwell;2010.

4. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295(18):2164–7.

5. Lo CY, Chan WF, Lang BH, Lam KY, Wan KY. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors? World J Surg. 2006; 30(5):759–66.

6. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003; 13(4):381–7.

7. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003; 98(1):31–40.

8. Yi KH, Park YJ, Koong SS, Kim JH, Na DG, Ryu JS, et al. Revised Korean Thyroid Association Management Guidelines for patients with thyroid nodules and thyroid cancer. Korean J Otorhinolaryngol-Head Neck Surg. 2011; 54(1):8–36.

9. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997; 79(3):564–73.

10. Cappelli C, Castellano M, Braga M, Gandossi E, Pirola I, De Martino E, et al. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a monoinstitutional experience. J Surg Oncol. 2007; 95(7):555–60.

11. Liou MJ, Lin JD, Chung MH, Liau CT, Hsueh C. Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol. 2005; 125(4):438–42.

12. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg. 2006; 30(1):91–9.

13. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010; 22(6):395–404.

14. Ito Y, Miyauchi A, Kihara M, Takamura Y, Kobayashi K, Miya A. Relationship between prognosis of papillary thyroid carcinoma patient and age: a retrospective single-institution study. Endocr J. 2012; 59(5):399–405.

15. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988; 104(6):947–53.

16. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004; 135(2):139–48.

17. Cho JK, Kim JY, Jeong CY, Jung EJ, Park ST, Jeong SH, et al. Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age. J Korean Surg Soc. 2012; 82(5):281–7.

18. Kim BY, Jung CH, Kim JW, Lee SW, Kim CH, Kang SK, et al. Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Yonsei Med J. 2012; 53(5):924–30.

19. Roh JL, Kim JM, Park CI. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol. 2008; 15(4):1177–82.

20. So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010; 148(3):526–31.

21. Kim SS, Lee BJ, Lee JC, Kim SJ, Jeon YK, Kim MR, et al. Coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma: the influence of lymph node metastasis. Head Neck. 2011; 33(9):1272–7.

22. Schaffler A, Palitzsch KD, Seiffarth C, Hohne HM, Riedhammer FJ, Hofstadter F, et al. Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur J Clin Invest. 1998; 28(10):838–44.

23. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167–214.

24. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 1999; 84(2):458–63.

25. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999; 126(6):1070–6. discussion 6-7.

26. Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005; 352(23):2406–12.

27. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K. et al. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg. 2004; 28(11):1115–21.

28. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer. 2004; 11(1):97–116.

29. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009; 16(2):240–5.

30. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Bernante P, Pagetta C, et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol. 2006; 32(10):1144–8.

Table 1.

Baseline characteristics of patients with papillary thyroid microcarcinoma

	Group 1 (n=230)	Group 2 (n=513)	Group 3 (n=77)
Age (years) MeanSD Range Gender (F/M)	35.935.840 (16-44) 204/26 (88.7/23)	53.325.223 (45-64) 465/48 (90.6/9.4)	69.903.747 (65-83) 69/8 (89.6/10.4)

Values are presented as meanSD or number (%). Group 1, patient's age < 45 years; Group 2, patient's 45 ≤ age < 65; Group 3, patient's age ≥ 65 years. F: female, M: male

Table 2.

Histopathological characteristics of patients with papillary thyroid microcarcinoma

	Group 1 (n=230)	Group 2 (n=513)	Group 3 (n=77)	p value
Hashimoto's thyroiditis				0.161
Present	15 (6.5)	19 (3.7)	2 (2.6)
Absent	215 (93.5)	494 (96.3)	75 (97.4)
Multifocality				0.717
Present	53 (23)	129 (25.1)	21 (27.3)
Absent	177 (77)	384 (74.9)	56 (72.7)
Extrathyroidal extension				0.948
Present	76 (33)	165 (32.2)	24 (31.2)
Absent	154 (67)	348 (67.8)	53 (68.8)
LN grade				0.159
N0	136 (59.1)	348 (67.8)	54 (70.1)
N1a	86 (37.4)	148 (28.8)	20 (26)
N1 b	8 (3.5)	17 (3.3)	3 (3.9)
TNM stage				< 0.001
I	230 (100)	255 (49.7)	40 (51.9)
II	0 (0)	0 (0)	0 (0)
III	0 (0)	242 (47.2)	34 (44.2)
IV	0 (0)	16 (3.1)	3 (3.9)
Stage				< 0.001
Early (stage I, II)	230 (100)	255 (49.7)	41 (53.2)
Advanced (stage III, IV)	0 (0)	258 (50.3)	36 (46.8)
BRAF^V600E mutation	81 (35.2)	193 (37.6)	25 (32.5)	0.589

Values are presented as number (%). Group 1, patient's age < 45 years; Group 2, patient's 45 ≤ age < 65; Group 3, patient's age ≥ 65 years

TOOLS

Similar articles